Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2020

View Archived Issues

Endothelial cells have functional deficits in progeria

More enhancers suggest more pathogenicity: study

Tarsius opens two phase I/II trials of TRS-01 eye drops

Positive preclinical data presented for QPG-1029

Phase II data for arimoclomol as treatment of sporadic inclusion body myositis

Immunitor presents interim phase III data for hepcortespenlisimut-L in HCC

FASN as a new prognostic biomarker in Wilms' tumor

G-721-0282, novel CHI3L1 ligand with anti-proliferative effects in models of osteosarcoma

Chinese researchers patent PI3K inhibitors

Novartis identifies new NLRP3 inflammasome inhibitors

Japanese investigators synthesize new PTPN11 inhibitors

Hanmi Science describes new FLT3 and/or FLT3 ITD mutant inhibitors

New SNF2L2 inhibitors presented by Epizyme

ApoE, largest genetic risk factor for AD, also affects synucleinopathies

11 potential blockbuster drugs offer hope, threaten budgets

Tumor-targeted siRNA/pDNA dual delivery system reprograms the tumor microenvironment

Paraoxonase 1 gene therapy offers long-term protection against lethal doses of nerve agents in mice

Mucolipin-1 found to be a potential therapeutic target for DMD

Amgen studies AMG-509 in phase I for metastatic CRPC

PsiOxus initiates phase I study of NG-641 in metastatic or advanced epithelial tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...